Affiliation:
1. Russian Research Institute of Hematology and Transfusiology, Federal Medical and Biological Agency; Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia
2. Russian Research Institute of Hematology and Transfusiology, Federal Medical and Biological Agency
Abstract
Polycythemia vera is a disease known since ancient times, however, until recent decades, diagnosis was carried out by exclusion, and therapy was symptomatic. The discovery of the pathogenetic role of mutations in the Janus kinase II gene has led to the possibility of establishing a diagnosis based not only on morphology, but also on genetic verification and to the development of directed targeted therapy, which is much more effective than previously used methods. The introduction of molecular genetic screening led to the need for a differential diagnosis with familial erythrocytosis, and the lessons of the coronavirus pandemic revealed the presence in the population of a significant proportion of patients with erythrocytosis due to the carriage of gene polymorphisms associated with familial hemochromatosis. The article presents our own personalized algorithms for the diagnosis and treatment of polycythemia vera and the results of their use, demonstrating the possibility of a two-fold reduction in the incidence of thrombosis and an increase in overall survival.
Publisher
Publishing House ABV Press
Reference62 articles.
1. Shuvaev V.A., Martynkevich I.S., Sidorkevich S.V. Myeloproliferative neoplasms. Moscow, 2023. 336 p.
2. Abdulkadyrov K.M., Shuvaev V.A., Martynkevich I.S. All we know about polycythemia vera: literature review and own experience. Onkogematologiya = Oncohematology 2015;10(3):28–42. (In Russ.). DOI: 10.17650/1818-8346-2015-10-3-28-42
3. Demidova A.V., Kotsubinsky N.N., Mazurov V.I. Erythremia and secondary erythrocytosis. Saint Petersburg: Izd-vo SPbMAPO, 2001. 228 p. (In Russ.).
4. Anía B.J., Suman V.J., Sobell J.L. et al. Trends in the incidence of polycythemia vera among Olmsted County, Minnesota residents, 1935–1989. Am J Hematol 1994;47(2):89–93. DOI: 10.1002/ajh.2830470205
5. Rollison D.E., Howlader N., Smith M.T. et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001–2004, using data from the NAACCR and SEER programs. Blood 2008;112(1):45–52. DOI: 10.1182/blood-2008-01-134858